Overview

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
0
Participant gender:
All
Summary
B-cell non-Hodgkin's lymphoma (B-NHL) is the most common type of NHL. Although novel immunotherapies represented by anti-CD20 monoclonal antibodies and CAR-T cell therapies have significantly improved the prognosis of B-NHL patients, there are still nearly one-third of patients who are resistant to initial treatment or relapse after remission. R-CHOP combined with novel drugs was expected to improve the prognosis. Therefore, this study aimed to investigate the potential of R-CHOP combined with Orelabrutinib.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shandong Provincial Hospital
Treatments:
Cyclophosphamide
Doxorubicin
Etoposide
Prednisone
Rituximab
Vincristine
Criteria
Inclusion Criteria:

1. Age ≥18 years, gender not limited

2. Newly and histologically diagnosed aggressive B-NHL

3. Patients who have not received systematic chemotherapy or immunotherapy;

4. Patients with at least ≥1 tumor foci with a measurable maximum axis exceeding 1.5 cm;

5. Eastern cancer collaboration group(ECOG) physical status score: 0-2

6. Major organ functions meet the following criteria:

1. Blood routine: (independent of growth factor support or transfusion within 7 days
of study entry) neutrophils absolute value ≥1.5×109/L, platelets ≥75×109/L,

2. Coagulation function:INR and APTT ≤2.5 times ULN,

3. Blood biochemistry:total bilirubin ≤2 times ULN, AST or ALT≤2.5 times ULN;

4. Renal function: Ccr ≥ 50 mL/min, total bilirubin, AST or ALT≤2.5 times ULN

7. Willing to take contraceptive measures during the trial period and within 3 months
after the trial ends;

8. Voluntarily sign written informed consent before screening.

Exclusion Criteria:

1. Current or previous malignancy, unless radical therapy has been performed and there is
no evidence of recurrence or metastasis in the past 5 years;

2. Patients scheduled for major surgery(examination for diagnostic purposes) within 4
weeks or participating in drug/device clinical trials;

3. Prior or concurrent indolent B-cell lymphoma transformation;

4. Have uncontrolled or significant cardiovascular disease, including:

1. New York Heart Association (NYHA) Grade II or higher congestive heart failure,
unstable angina, and myocardial infarction occurred within 6 months before the
first administration of the study drug or arrhythmia needing treatment at the
time of screening, LVEF <50%;

2. Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic
cardiomyopathy, arrhythmic right ventricular cardiomyopathy, restrictive
cardiomyopathy, indeterminate cardiomyopathy);

3. Clinically significant QTc interval prolongation history, or QTc interval >470ms
for female and >450ms for male in the screening period;

4. Symptomatic coronary heart disease patients or needing treatment;

5. Uncontrolled high blood pressure (on the basis of improving lifestyle,
substandard blood pressure with reasonable and tolerable application of 2 or more
antihypertensive drugs including diuretics for more than 1 month, or taking 4 or
more antihypertensive drugs to control blood pressure effectively);

5. Had active bleeding within 2 months prior to screening, or was taking anticoagulant
drugs, or was considered by the investigator to have a clear tendency to bleeding;

6. Stroke or intracranial hemorrhage within 6 months;

7. Subjects with clinically significant gastrointestinal abnormalities that may affect
drug intake, transport or absorption (such as inability to swallow, chronic diarrhea,
intestinal obstruction, etc.);

8. Active or uncontrolled HBV (HBsAg positive and HBV DNA titer positive), HCV Ab
positive or HIV positive;

9. Uncontrolled, active systemic fungal, bacterial, viral, or other infections (defined
as showing persistent signs/symptoms related to infection, despite the use of
appropriate antibiotics or other treatments without improvement);

10. Allergies or hypersensitivity reactions to orelabrutinib, rituximab or any other
component of the applicable study drug;

11. Combined with drugs with moderate to severe inhibitory effect or strong induction
effect on CYP3A;

12. Severe mental illness;

13. Expected survival <6 months

14. Pregnant and lactating women; For women of childbearing age who do not agree to use
appropriate methods of contraception;

15. Poor compliance or inability to visit regularly;

16. Potentially life-threatening patients, or severe organ dysfunction, judged unsuitable
for this trail by investigators.